UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisd ...

M a y 6 t h , 2 0 2 2 Full-Year FY 22 Results & Business Attributes Review HEALTHCARE Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, diluted EPS, free cash flow, and organic revenue growth; the Company's ability to perform well in the currently evolving environment, including in light of the impact o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO ______ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Inco ...

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q4 2022 Earnings Conference Call May 6, 2022 8:30 AM ET Company Participants Phil Terpolilli - VP, IR Ron Lombardi - Chairman, President and CEO Christine Sacco - CFO Conference Call Participants Rupesh Parikh - Oppenheimer Stephanie Wissink - Jefferies Jon Anderson - William Blair Linda Bolton Weiser - D.A. Davidson Anthony Lebiedzinski - Sidoti Operator Good day ladies and gentlemen, thank you for standing by. And welcome to the Prestige Consumer Healthcare, In ...

Financial Data and Key Metrics Changes - Revenues for Q3 2022 were $275 million, representing a 15% increase compared to the prior year, consistent with year-to-date trends [7][18] - EBITDA increased by approximately 11%, with EBITDA margins remaining stable in the mid-30s [20] - Diluted earnings per share for the quarter was $0.99, up 22% year-over-year, driven by higher sales and lower interest expenses [20] Business Line Data and Key Metrics Changes - North America revenues increased by about 14%, with significant organic growth in GI, ear and eye care, and cough and cold categories [18] - The international segment saw an approximate 18% increase in Q3, benefiting from strong sales of the Hydralyte brand [19] Market Data and Key Metrics Changes - The company experienced a rebound in cough and cold product sales, which had been impacted by COVID-19, contributing to incremental sales in Q3 [8][13] - E-commerce channel consumption growth continued to be double digits year-over-year, reflecting a shift in consumer purchasing behavior [21] Company Strategy and Development Direction - The company is focused on leveraging its diversified portfolio to drive long-term growth and navigate supply chain challenges [15][28] - Capital allocation priorities include continued de-levering, considering M&A opportunities, and opportunistic stock buybacks [35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the business momentum and anticipated continued growth despite potential headwinds from COVID-19 disruptions [28][30] - The company raised its full-year revenue outlook to between $1.75 billion and $1.80 billion, with an expected organic growth of about 9% [28] Other Important Information - The company generated approximately $65 million in free cash flow for Q3, up double digits from the prior year [9] - The acquisition of Akorn consumer brands is performing well and aligns with the company's expectations [10] Q&A Session Summary Question: Outlook for next year regarding growth - Management indicated optimism about growth, expecting organic growth even after record results in the current year [34] Question: Capital allocation strategy if below targeted debt-to-EBITDA ranges - Capital allocation priorities will remain consistent, focusing on de-levering, M&A opportunities, and stock buybacks [35] Question: Magnitude of inflationary pressures faced - Management noted $10 million to $15 million of inflationary pressure and indicated that pricing actions have been taken across the majority of the portfolio [36] Question: E-commerce growth and its future - E-commerce growth is expected to continue outpacing brick-and-mortar growth, with ongoing investments in this channel [42] Question: Supply chain concerns - Management expressed confidence in their diverse supplier base and did not identify any specific inputs of concern [85] Question: Innovations and share gains in products - New product launches have occurred, with notable share gains in brands like Dramamine and Clear Eyes [67] Question: Changes in consumer behavior post-COVID - Management noted a long-term trend towards increased consumer focus on health and wellness, which aligns with the company's product offerings [54]

RIPLE CLEAI 0 ULTIMATE 50 ma February 3rd, 2022 Prestige Consumer HEALTHCARE Third Quarter FY 2022 Results Safe Harbor Disclosure 2 This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, adjusted diluted EPS, and free cash flow; the Company's ability to perform well in the currently evolving environment and execute on its brand-bu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) 660 White Plains R ...

Financial Data and Key Metrics Changes - The company reported record revenues of $276 million for Q2 2022, an increase of 16% compared to the prior year, driven by strong consumer behaviors and brand building efforts [5][19] - Adjusted EPS for the quarter was $1.02, up over 31% year-over-year, primarily due to higher sales and lower interest expenses [6][21] - Adjusted free cash flow reached $62 million, also reflecting a double-digit increase from the previous year [6][21] - For the first half of fiscal 2022, revenues increased by 17%, with organic growth of 13% after excluding the acquisition impact [23] Business Line Data and Key Metrics Changes - North America revenues increased approximately 16%, with significant organic growth in GI, cough and cold, and dermatological categories [19] - The acquisition of Akorn's Consumer Brands contributed $12.4 million in revenue during the quarter [6][19] - E-commerce sales continued to grow double digits, now accounting for over 10% of total sales, driven by investments in online content and digital advertising [14][16] Market Data and Key Metrics Changes - International OTC revenues increased approximately 15% in Q2, benefiting from a favorable comparison to the prior year and increased sales of Hydralyte in Australia [20] - The company experienced a rebound in travel trends, positively impacting brands like Dramamine and Clear Eyes [9][20] Company Strategy and Development Direction - The company is focused on a disciplined capital allocation strategy, emphasizing debt reduction and maintaining a strong financial profile [27][28] - The management expressed confidence in navigating the dynamic market environment and raised the full-year revenue outlook to $1.05 billion to $1.06 billion [29][30] - The company plans to continue executing cost-saving measures and pricing actions to mitigate inflationary pressures [24][46] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing uncertainty in the business environment due to COVID-19 but highlighted the company's strong portfolio and brand positioning [4][29] - The company anticipates continued consumer demand trends and a modest recovery in cough/cold and head lice categories [30] - Management expects adjusted EPS for fiscal 2022 to be in the range of $3.93 to $3.98, reflecting strong cash generation and financial leverage [31] Other Important Information - The company maintained a gross margin of 58.4% for the first half of fiscal 2022, with expectations of approximately 57% for the full year due to rising supply chain costs [24][46] - The company generated $129.7 million in free cash flow for the first half, up about 12% year-over-year [27] Q&A Session Summary Question: Guidance on organic growth in the second half - Management explained that the organic growth in the first half was strong, but the second half may see a deceleration due to seasonality and tough comparisons from the previous year [34][36] Question: Comparison of shipments and consumption - Management indicated that consumption and organic sales trends were aligned, both around 10% [38] Question: Retail inventory levels - Management noted that retail inventory levels are generally in good shape, despite some supply chain stresses [40][41] Question: E-commerce performance - Management confirmed that e-commerce continues to grow and remains a strong channel for the company [43] Question: Gross margin pressures - Management acknowledged expected pressures on gross margins but expressed confidence in recovering to historic levels over time [45][46] Question: Consumer stock-up trends - Management estimated that about half of the sales increase in the quarter was due to timing related to consumer stock-up behavior [48] Question: TheraTears integration - Management reported no surprises in the integration of TheraTears, maintaining optimism about its long-term growth potential [49] Question: Drug channel performance - Management observed increased foot traffic in the drug channel, positively impacting sales [51] Question: Advertising and marketing spend - Management anticipated some inflation in advertising and marketing costs but planned to focus on effective investment areas [60]

N o v e m b e r 4 t h , 2 0 2 1 Second Quarter FY 2022 Results P C H C O N F I D E N T I A L A N D P R O P R I E T A R Y I N F O R M A T I O N Safe Harbor Disclosure 2 This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, adjusted EPS, free cash flow, and organic revenue growth; the Company's ability to perform well in the curren ...

[PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section presents the unaudited condensed consolidated financial statements and management's analysis of financial performance [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including income, balance sheet, and cash flow data, along with explanatory notes for key accounting policies and events [Condensed Consolidated Statements of Income and Comprehensive Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Income) This section details the company's revenues, gross profit, operating income, net income, and diluted EPS for the specified periods Consolidated Statement of Income Highlights (Unaudited) | Metric | Three Months Ended Sep 30, 2021 (In thousands) | Three Months Ended Sep 30, 2020 (In thousands) | Six Months Ended Sep 30, 2021 (In thousands) | Six Months Ended Sep 30, 2020 (In thousands) | | :--- | :--- | :--- | :--- | :--- | | **Total Revenues** | $276,225 | $237,422 | $545,406 | $466,816 | | **Gross Profit** | $157,712 | $137,661 | $316,724 | $271,529 | | **Operating Income** | $78,558 | $72,903 | $169,900 | $153,022 | | **Net Income** | $45,325 | $44,589 | $103,080 | $88,295 | | **Diluted EPS** | $0.89 | $0.88 | $2.03 | $1.74 | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides a snapshot of the company's assets, liabilities, and stockholders' equity at the end of the reporting periods Consolidated Balance Sheet Highlights (Unaudited) | Metric | September 30, 2021 (In thousands) | March 31, 2021 (In thousands) | | :--- | :--- | :--- | | **Total Current Assets** | $304,810 | $269,835 | | **Goodwill** | $578,797 | $578,079 | | **Intangible Assets, net** | $2,689,920 | $2,475,729 | | **Total Assets** | $3,675,818 | $3,429,273 | | **Long-term Debt, net** | $1,592,981 | $1,479,653 | | **Total Liabilities** | $2,214,171 | $2,070,975 | | **Total Stockholders' Equity** | $1,461,647 | $1,358,298 | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section outlines the cash inflows and outflows from operating, investing, and financing activities for the reporting periods Consolidated Statement of Cash Flows Highlights (Unaudited) | Metric | Six Months Ended Sep 30, 2021 (In thousands) | Six Months Ended Sep 30, 2020 (In thousands) | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $130,499 | $127,293 | | **Net cash used in investing activities** | ($232,989) | ($11,619) | | **Net cash provided by (used in) financing activities** | $114,184 | ($186,666) | | **Increase (decrease) in cash and cash equivalents** | $10,516 | ($68,157) | - The significant increase in cash used in investing activities was driven by the **$228.9 million** acquisition of Akorn's consumer health business[23](index=23&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations of significant accounting policies, recent acquisitions, debt refinancing, and other material financial events - The company completed the acquisition of consumer health business assets from Akorn on July 1, 2021, for a purchase price of **$228.9 million** in cash. This acquisition added the *TheraTears* brand and other over-the-counter consumer brands to the company's portfolio[33](index=33&type=chunk) - The COVID-19 pandemic has had a mixed impact, with some categories like Women's Health and Oral Care benefiting, while others like Cough & Cold were negatively impacted. However, the pandemic has not had a material negative impact on overall operations, sales, or liquidity to date[26](index=26&type=chunk)[27](index=27&type=chunk) - As of September 30, 2021, total long-term debt stood at **$1.62 billion**. The company refinanced its term loan on July 1, 2021, to fund the Akorn acquisition and extend the maturity date to July 1, 2028[53](index=53&type=chunk)[54](index=54&type=chunk) - The company has significant customer concentration risk, with Walmart accounting for approximately **22.7%** and **21.2%** of gross revenues for the three and six months ended September 30, 2021, respectively[86](index=86&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management analyzes the company's financial performance, liquidity, and capital resources, highlighting revenue growth, margin pressures, and the impact of the Akorn acquisition [Results of Operations (Three Months Ended Sep 30, 2021 vs 2020)](index=31&type=section&id=Results%20of%20Operations%20%28Three%20Months%20Ended%20Sep%2030%2C%202021%20vs%202020%29) This section details the company's financial performance for the three months ended September 30, 2021, compared to the prior year, focusing on revenue and expense drivers - Total revenues increased by **16.3%** to **$276.2 million**, driven by a **16.2%** increase in the North American OTC segment and a **17.5%** increase in the International OTC segment[112](index=112&type=chunk) - The North American revenue growth was primarily driven by the Eye & Ear Care category, which included the newly acquired *TheraTears* brand, and recovery in the Cough & Cold and Gastrointestinal categories as COVID-19 restrictions eased[113](index=113&type=chunk) - Gross profit margin decreased slightly from **58.0%** to **57.1%**, primarily due to increased supply chain costs and a **$1.6 million** charge related to the inventory valuation of the acquired Akorn brands[116](index=116&type=chunk) - General and administrative expenses increased from **$20.4 million** to **$32.3 million**, largely due to **$5.1 million** in costs related to the Akorn acquisition[124](index=124&type=chunk) [Results of Operations (Six Months Ended Sep 30, 2021 vs 2020)](index=34&type=section&id=Results%20of%20Operations%20%28Six%20Months%20Ended%20Sep%2030%2C%202021%20vs%202020%29) This section analyzes the company's financial results for the six months ended September 30, 2021, compared to the prior year, focusing on revenue, gross profit, and net interest expense - Total revenues for the six-month period increased by **16.8%** to **$545.4 million**. The North American segment grew **15.7%**, and the International segment grew **29.6%**[131](index=131&type=chunk) - Gross profit increased **16.6%** to **$316.7 million**, with the gross margin remaining relatively stable at **58.1%** compared to **58.2%** in the prior year[135](index=135&type=chunk) - Net interest expense decreased to **$31.4 million** from **$43.2 million**, driven by a lower average cost of borrowing (**4.0%** vs. **5.1%**) and slightly lower average indebtedness[144](index=144&type=chunk) [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20Capital%20Resources) This section evaluates the company's cash flow generation, capital allocation, debt structure, and compliance with financial covenants - Net cash provided by operating activities was strong at **$130.5 million** for the six months ended September 30, 2021[149](index=149&type=chunk) - The company used **$228.9 million** for the acquisition of Akorn, which was the primary driver of the **$233.0 million** in net cash used in investing activities[150](index=150&type=chunk) - On July 1, 2021, the company refinanced its term loan, creating a new class of Term B-5 Loans in an aggregate principal amount of **$600.0 million** to fund the Akorn acquisition and extend the maturity to 2028[153](index=153&type=chunk)[154](index=154&type=chunk) - As of September 30, 2021, total outstanding indebtedness was **$1.6 billion**, and the company was in compliance with all debt covenants[152](index=152&type=chunk)[157](index=157&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section details the company's exposure to market risks, including interest rate fluctuations on variable-rate debt and foreign currency exchange rate volatility - A hypothetical **1.0%** increase in interest rates on the company's variable rate debt would adversely impact pre-tax earnings by approximately **$1.1 million** for the quarter[169](index=169&type=chunk) - Approximately **11.8%** of gross revenues for the quarter were denominated in currencies other than the U.S. Dollar, primarily Canadian and Australian Dollars. A hypothetical **10%** adverse change in exchange rates would impact pre-tax income by approximately **$1.8 million** for the quarter[170](index=170&type=chunk)[171](index=171&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that as of September 30, 2021, the company's disclosure controls and procedures were effective[172](index=172&type=chunk) - No changes occurred during the quarter ended September 30, 2021, that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[173](index=173&type=chunk) [PART II. OTHER INFORMATION](index=42&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section provides additional information, including updates on risk factors and a list of exhibits filed with the quarterly report [Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) This section confirms no material changes to the risk factors previously disclosed in the Annual Report on Form 10-K for the fiscal year ended March 31, 2021 - The risk factors described in the company's Annual Report on Form 10-K for the year ended March 31, 2021, have not materially changed during the period covered by this quarterly report[174](index=174&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including amendments to credit agreements and required officer certifications - Key exhibits filed include Amendment No. 6 to the Term Loan Credit Agreement and CEO/CFO certifications pursuant to the Securities Exchange Act of 1934[178](index=178&type=chunk)